Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
78.2% Return Seen to Date on SmarTrend Juno Therapeutic Call (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 7 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Up 78.2% Since SmarTrend Uptrend Call (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 7 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Has Returned 78.2% Since SmarTrend Recommendation (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 6 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Has Returned 78.2% Since SmarTrend Recommendation (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 5 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Uptrend Call Working As Juno Therapeutic Stock Rises 78.2% (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 5 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Up 78.2% Since SmarTrend Uptrend Call (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 5 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Shares Up 78.2% Since SmarTrend's Buy Recommendation (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 5 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Uptrend Call Working As Juno Therapeutic Stock Rises 78.2% (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 4 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Uptrend Call Working As Juno Therapeutic Stock Rises 78.2% (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 4 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Shares Up 78.2% Since SmarTrend's Buy Recommendation (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 4 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
78.2% Return Seen to Date on SmarTrend Juno Therapeutic Call (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 3 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Uptrend Call Working As Juno Therapeutic Stock Rises 78.2% (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 3 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Shares Up 78.2% Since SmarTrend's Buy Recommendation (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 3 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Juno Therapeutic Has Returned 78.2% Since SmarTrend Recommendation (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 3 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
78.2% Return Seen to Date on SmarTrend Juno Therapeutic Call (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 2 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
3 Top Stocks Wall Street Is Overlooking
Tags CELG JUNO SAM
From Motley Fool
Juno Therapeutic Up 78.2% Since SmarTrend Uptrend Call (JUNO)
SmarTrend identified an Uptrend for Juno Therapeutic (NASDAQ:JUNO) on January 5th, 2018 at $48.79. In approximately 2 months, Juno Therapeutic has returned 78.23% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Editas Medicine Delivers Another Strong Quarter
Tags JUNO EDIT
From Motley Fool
An Eventful February Took Its Toll On TD Ameritrade's Investor Index
After nearly two solid years of plotting a strong upward trajectory, TD Ameritrade's investor Movement Index took its first decisive ... 
Tags COP JUNO SNY
From Benzinga
Biotechs Buffeted by Macro News But Should Continue to Outperform
Biotechs outperform in 2018 having recovered most of their losses from last week’s volatility caused by dire tariff talk and higher interest rates, raising concerns about the impact on global growth. 
Tags Stocks / Equities ETFs Pharma/Biotech
From Blogs - TalkMarkets
Investor Movement Index February Summary
The IMX posted the largest monthly decrease ever in February, as volatility returned to the market, decreasing over -23% to 5.95. The ... 
Tags MSFT GE FB
From Benzinga
Biotech ETFs Head to Head: XBI vs. IBB
The biotech sector has been attracting a lot of investor attention lately. This sector is expected to continue benefiting from increased M&A activities, new drug approvals, better R&D and innovations. 
Tags ETFs Stocks / Equities
From Blogs - TalkMarkets
Biotech Crushing the Market: Best ETFs & Stocks YTD
Biotechnology sector, which includes the fast-growing companies in the health care world, are easily crushing the overall market and broader health care sector so far this year. 
Tags Stocks / Equities ETFs
From Blogs - TalkMarkets
Noteworthy ETF Outflows: XBI, ARRY, JUNO, LOXO
Symbols mentioned in this story: XBI, ARRY, JUNO, LOXO Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
Juno Therapeutic Rising on Above-Average Volume, Consistent With Trend (JUNO)
Shares of Juno Therapeutic are trading up 0.0% to $86.59 today on above average volume. About 1.3 million shares have been traded today, as compared to the 30-day average... 
From Comtex SmarTrend® News Briefs
3 Biotech Stocks That Soared This Week: Are They Buys?
Tags JUNO VYGR ABBV
From Motley Fool
3 Big Drugmakers Boosting Huge R&D Budgets
Tags BMY CELG JUNO
From Motley Fool
Juno Therapeutics (JUNO) remains a Buy This Week
 
Tags NASDAQ:JUNO Hot Stocks
From InvestorPlace
Dow's Merck Jumps On Merger Bandwagon With $394 Million Buy
Dow's Merck announced its plan Wednesday to acquire Australian cancer outfit Viralytics in a $394 million deal. 
From Investor's Business Daily
Juno Therapeutic Trading Higher Today on Above-Average Volume, Consistent With Trend (JUNO)
Juno Therapeutic's stock is up 2.0% to $86.71 on heavy trading volume. Today's volume of 4.7 million shares tops the average 30-day volume of 1.0 million shares. Unusually... 
From Comtex SmarTrend® News Briefs
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.